img
Predictors of response to pegylated interferon treatment in HBeAg negative patients with chronic hepatitis B        
Yazarlar
Ertuğrul Güçlü
Sakarya Üniversitesi, Türkiye
Tuna Nazan
Oğuz Karabay
Sakarya Üniversitesi, Türkiye
Sıla Akhan
Kocaeli Üniversitesi, Türkiye
Hürrem Bodur
Bahadır Ceylan
İstanbul Medipol Üniversitesi, Türkiye
Tuna Demirdal
İzmir Katip Çelebi Üniversitesi, Türkiye
Kutbettin Demirdağ
Neşe Demirtürk
Afyon Kocatepe Üniversitesi, Türkiye
Hasan Çetin Ekerbiçer
Sakarya Üniversitesi, Türkiye
Serpil Erol
Şaban Esen
Ondokuz Mayıs Üniversitesi, Türkiye
Ömer Evirgen
Mustafa Kemal Üniversitesi, Türkiye
Mehmet Faruk Geyik
Düzce Üniversitesi, Türkiye
Alper Gündüz
Prof. Dr. Mustafa Kasım KARAHOCAGİL Prof. Dr. Mustafa Kasım KARAHOCAGİL
Yüzüncü Yıl Üniversitesi, Türkiye
Ömer Faruk Kökoğlu
Kahramanmaraş Sütçü İmam Üniversitesi, Türkiye
Davut Özdemir
Düzce Üniversitesi, Türkiye
Nail Özgüneş
Fatma Sargın
Selma Tosun
Ediz Tütüncü
Özet
Introduction: Although pegylated interferons (pegIFNs) alpha-2a and alpha-2b have been used in chronic hepatitis B (CHB) treatment for many years, there are few studies concerning predictors of sustained virologic response (SVR) to pegIFN therapy. In this study, we aimed to investigate the predictors of response to pegIFN treatment in cases with HBeAg-negative CHB infection.
Methodology: Seventeen tertiary care hospitals in Turkey were included in this study. Data from consecutively treated HBeAg-negative CHB patients, who received either pegIFN alpha-2a or alpha-2b, were collected retrospectively. SVR is defined as an HBV DNA concentration of less than 2,000 IU/mL six months after the completion of therapy
Results: SVR was achieved in 40 (25%) of the 160 HBeAg-negative CHB patients. Viral loads in patients with SVR were lower compared to those with no SVR, beginning in the third month of treatment (p < 0.05). The number of cases with a decline of 1 log(10) IU/mL in viral load after the first month of treatment and with a serum HBV DNA level under 2,000 IU/mL after the third month of treatment was higher in cases with SVR (p < 0.05). The number of patients who had undetectable HBV DNA levels at week 48 among responders was significantly greater than among post-treatment virological relapsers (p < 0.05).
Conclusions: Detection of a 1 log(10) decline in serum HBV DNA level at the first month of treatment and a serum HBV DNA level < 2000 IU/mL at the third month of therapy may be predictors of SVR.
Anahtar Kelimeler
Hepatitis B | Interferon | Sustained virological response | Viral load
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale
Dergi Adı JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
Dergi ISSN 1972-2680
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce
Basım Tarihi 12-2014
Cilt No 8
Sayı 12
Sayfalar 1601 / 1608
Doi Numarası 10.3855/jidc.4953
Makale Linki http://www.jidc.org/index.php/journal/article/view/4953